AVROBIO Key Executives
This section highlights AVROBIO's key executives, including their titles and compensation details.
Find Contacts at AVROBIO
(Showing 0 of )
AVROBIO Earnings
This section highlights AVROBIO's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
$1.40
Stock Price
$5.24M
Market Cap
51
Employees
Cambridge, MA
Location
Financial Statements
Access annual & quarterly financial statements for AVROBIO, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $617.00K | $4.17M | $1.40M | $1.21M | $850.00K |
| Gross Profit | $-617.00K | $-4.17M | $-1.40M | $-1.21M | $-850.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $47.08M | $72.19M | $83.11M | $87.24M | $54.97M |
| General and Administrative Expenses | $22.69M | $33.25M | $35.73M | $32.99M | $20.84M |
| Selling and Marketing Expenses | $23.94M | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $23.97M | $33.25M | $35.73M | $32.99M | $20.84M |
| Other Expenses | $- | $-456.00K | $-285.00K | $516.00K | $2.84M |
| Operating Expenses | $71.05M | $105.43M | $118.84M | $120.23M | $75.81M |
| Cost and Expenses | $71.67M | $105.43M | $118.84M | $120.23M | $75.81M |
| Interest Income | $2.42M | $299 | $- | $719.00K | $2.93M |
| Interest Expense | $2.42M | $299.00K | $- | $- | $- |
| Depreciation and Amortization | $617.00K | $1.44M | $1.40M | $1.21M | $850.00K |
| EBITDA | $-71.05M | $-105.43M | $-118.84M | $-120.23M | $-75.81M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-71.67M | $-105.43M | $-118.84M | $-120.23M | $-75.81M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $2.34M | $-456.00K | $-285.00K | $516.00K | $2.84M |
| Income Before Tax | $12.53M | $-105.89M | $-119.13M | $-119.71M | $-72.97M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $377.00K | $157.00K | $-1.40M | $-1.21M | $-850.00K |
| Net Income | $12.16M | $-106.05M | $-117.73M | $-118.50M | $-72.11M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $0.27 | $-2.42 | $-2.75 | $-3.27 | $-2.63 |
| EPS Diluted | $0.27 | $-2.42 | $-2.75 | $-3.27 | $-2.63 |
| Weighted Average Shares Outstanding | 44.33M | 43.74M | 42.85M | 36.21M | 27.43M |
| Weighted Average Shares Outstanding Diluted | 44.57M | 43.74M | 42.85M | 36.21M | 27.43M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $3.60M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $1.80M | $- | $879.00K | $920.00K | $3.06M | $336.00K | $354.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $- | $1.80M | $- | $-879.00K | $-920.00K | $-3.06M | $-336.00K | $-354.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 50.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $463.00K | $4.39M | $14.83M | $11.15M | $17.33M | $18.14M | $15.92M | $18.88M | $19.25M | $19.00M | $23.04M | $22.54M | $18.53M | $19.59M | $28.51M | $20.87M | $18.27M | $17.22M | $13.04M | $12.27M |
| General and Administrative Expenses | $7.26M | $5.24M | $6.26M | $4.58M | $7.89M | $7.12M | $7.07M | $8.90M | $10.16M | $8.96M | $9.58M | $8.83M | $8.36M | $8.48M | $8.21M | $7.99M | $8.31M | $6.21M | $5.02M | $4.34M |
| Selling and Marketing Expenses | $-105.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $7.15M | $5.24M | $6.26M | $4.58M | $7.89M | $7.12M | $7.07M | $8.90M | $10.16M | $8.96M | $9.58M | $8.83M | $8.36M | $8.48M | $8.21M | $7.99M | $8.31M | $6.21M | $5.02M | $4.34M |
| Other Expenses | $-13.00K | $-6.00K | $-51.00K | $-36.00K | $263.00K | $223.00K | $-95.00K | $5.00K | $-45.00K | $-265.00K | $5.00K | $-21.00K | $-25.00K | $-67.00K | $-74.00K | $-33.00K | $-16.00K | $771.00K | $-6.00K | $-8.00K |
| Operating Expenses | $7.62M | $9.63M | $21.09M | $15.73M | $25.22M | $25.26M | $22.98M | $27.77M | $29.42M | $27.96M | $32.62M | $31.38M | $26.88M | $28.06M | $36.72M | $28.86M | $26.59M | $23.43M | $18.06M | $16.61M |
| Cost and Expenses | $7.62M | $9.63M | $21.09M | $15.73M | $25.22M | $25.26M | $22.98M | $27.77M | $29.42M | $27.96M | $32.62M | $31.38M | $26.88M | $28.06M | $36.72M | $28.86M | $26.59M | $23.43M | $18.06M | $16.61M |
| Interest Income | $- | $1.26M | $1.41M | $444 | $248.00K | $245 | $111.00K | $- | $- | $- | $2.00K | $9.00K | $10.00K | $13.00K | $12.00K | $62.00K | $632.00K | $788.00K | $925.00K | $565.00K |
| Interest Expense | $- | $270.00K | $1.41M | $495.00K | $248.00K | $188.00K | $111.00K | $285.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $43.28K | $43.81K | $3.68M | $289.00K | $328.00K | $335.00K | $352.00K | $354.00K | $399.00K | $436.00K | $374.00K | $298.00K | $291.00K | $309.00K | $314.00K | $301.00K | $283.00K | $245.00K | $215.00K | $200.00K |
| EBITDA | $-7.62M | $-9.63M | $-19.25M | $-15.48M | $-25.22M | $-25.26M | $-22.63M | $-27.42M | $-29.02M | $-27.96M | $-32.25M | $-31.08M | $-26.59M | $-28.06M | $-36.40M | $-28.56M | $-26.31M | $-23.43M | $-17.85M | $-16.41M |
| EBITDA Ratio | 0.00% | -267.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-7.62M | $-9.63M | $-22.93M | $68.01M | $-25.22M | $-25.26M | $-22.98M | $-27.77M | $-29.42M | $-27.96M | $-32.62M | $-31.38M | $-26.88M | $-28.06M | $-36.72M | $-28.86M | $-26.59M | $-23.43M | $-18.06M | $-16.61M |
| Operating Income Ratio | 0.00% | -267.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $808.00K | $1.22M | $1.36M | $-531.00K | $263.00K | $223.00K | $16.00K | $-280.00K | $-415.00K | $-265.00K | $7.00K | $-12.00K | $-15.00K | $-67.00K | $-62.00K | $29.00K | $616.00K | $771.00K | $919.00K | $557.00K |
| Income Before Tax | $-6.81M | $-8.41M | $-21.58M | $67.48M | $-24.96M | $-25.03M | $-22.97M | $-28.05M | $-29.83M | $-28.23M | $-32.61M | $-31.39M | $-26.90M | $-28.13M | $-36.78M | $-28.83M | $-25.97M | $-22.66M | $-17.14M | $-16.05M |
| Income Before Tax Ratio | 0.00% | -233.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $-154.25K | $377.00K | $-3.25M | $459.00K | $-839.00K | $-57.60M | $-127.00K | $280.00K | $415.00K | $489.00K | $-2.00K | $-9.00K | $-10.00K | $-309.00K | $-12.00K | $-62.00K | $-632.00K | $-245.00K | $-925.00K | $-565.00K |
| Net Income | $-6.81M | $-8.79M | $-21.58M | $67.48M | $-24.12M | $32.57M | $-22.84M | $-28.33M | $-30.25M | $-28.23M | $-32.61M | $-31.39M | $-26.90M | $-28.13M | $-36.78M | $-28.83M | $-25.97M | $-22.66M | $-17.14M | $-16.05M |
| Net Income Ratio | 0.00% | -244.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.15 | $-0.20 | $-0.48 | $1.53 | $-0.55 | $0.74 | $-0.52 | $-0.65 | $-0.69 | $-0.65 | $-0.75 | $-0.74 | $-0.65 | $-0.73 | $-1.01 | $-0.80 | $-0.77 | $-0.72 | $-0.57 | $-0.67 |
| EPS Diluted | $-0.15 | $-0.20 | $-0.48 | $1.52 | $-0.55 | $0.74 | $-0.52 | $-0.65 | $-0.69 | $-0.65 | $-0.75 | $-0.74 | $-0.65 | $-0.73 | $-1.01 | $-0.80 | $-0.77 | $-0.72 | $-0.57 | $-0.67 |
| Weighted Average Shares Outstanding | 44.79M | 44.65M | 44.53M | 44.13M | 44.04M | 43.79M | 43.77M | 43.70M | 43.70M | 43.65M | 43.62M | 42.51M | 41.62M | 38.53M | 36.44M | 36.10M | 33.67M | 31.63M | 30.30M | 24.05M |
| Weighted Average Shares Outstanding Diluted | 44.79M | 44.65M | 44.53M | 44.28M | 44.04M | 43.79M | 43.77M | 43.70M | 43.70M | 43.65M | 43.62M | 42.51M | 41.62M | 38.53M | 36.44M | 36.10M | 33.67M | 31.63M | 30.30M | 24.05M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $98.30M | $92.56M | $189.57M | $259.68M | $187.04M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $98.30M | $92.56M | $189.57M | $259.68M | $187.04M |
| Net Receivables | $- | $269.00K | $2.70M | $2.56M | $2.14M |
| Inventory | $- | $-269.00K | $-2.70M | $-2.56M | $-2.14M |
| Other Current Assets | $1.96M | $7.39M | $9.58M | $7.56M | $8.66M |
| Total Current Assets | $100.26M | $99.67M | $199.15M | $267.24M | $195.70M |
| Property Plant Equipment Net | $432.00K | $3.95M | $4.13M | $3.06M | $3.70M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $400.00K | $- | $492.00K | $492.00K | $492.00K |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $323.00K | $74.00K | $436.00K | $625.00K |
| Total Non-Current Assets | $832.00K | $4.27M | $4.69M | $3.99M | $4.81M |
| Other Assets | $-0 | $- | $0 | $0 | $-0 |
| Total Assets | $101.09M | $103.95M | $203.84M | $271.23M | $200.51M |
| Account Payables | $27.00K | $384.00K | $3.49M | $2.68M | $3.95M |
| Short Term Debt | $878.00K | $999.00K | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $5.45M | $11.73M | $15.90M | $13.93M | $10.07M |
| Total Current Liabilities | $6.35M | $12.12M | $19.39M | $16.61M | $14.02M |
| Long Term Debt | $- | $16.46M | $14.95M | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $-999.00K | $30.00K | $276.00K | $484.00K |
| Total Non-Current Liabilities | $- | $16.46M | $14.97M | $276.00K | $484.00K |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $6.35M | $28.58M | $34.36M | $16.89M | $14.50M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $4.00K | $4.00K | $4.00K | $4.00K | $3.00K |
| Retained Earnings | $-477.27M | $-489.43M | $-383.54M | $-264.42M | $-144.70M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $-0 | $0 | $0 |
| Other Total Stockholders Equity | $572.01M | $564.80M | $553.01M | $518.76M | $330.71M |
| Total Stockholders Equity | $94.74M | $75.37M | $169.48M | $254.34M | $186.01M |
| Total Equity | $94.74M | $75.37M | $169.48M | $254.34M | $186.01M |
| Total Liabilities and Stockholders Equity | $101.09M | $103.95M | $203.84M | $271.23M | $200.51M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $101.09M | $103.95M | $203.84M | $271.23M | $200.51M |
| Total Investments | $400.00K | $- | $492.00K | $492.00K | $492.00K |
| Total Debt | $878.00K | $17.46M | $14.95M | $- | $- |
| Net Debt | $-97.42M | $-75.10M | $-174.62M | $-259.68M | $-187.04M |
Balance Sheet Charts
| Breakdown | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $90.76M | $98.30M | $105.84M | $124.69M | $72.33M | $92.56M | $115.97M | $132.41M | $161.66M | $189.57M | $201.37M | $226.44M | $233.03M | $259.68M | $219.55M | $244.38M | $257.69M | $187.04M | $206.36M | $90.35M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $90.76M | $98.30M | $105.84M | $124.69M | $72.33M | $92.56M | $115.97M | $132.41M | $161.66M | $189.57M | $201.37M | $226.44M | $233.03M | $259.68M | $219.55M | $244.38M | $257.69M | $187.04M | $206.36M | $90.35M |
| Net Receivables | $- | $- | $- | $270.00K | $270.00K | $269.00K | $2.98M | $2.96M | $2.84M | $2.70M | $2.66M | $2.33M | $2.74M | $2.56M | $2.37M | $2.14M | $2.18M | $2.14M | $2.12M | $1.71M |
| Inventory | $- | $- | $- | $3.09M | $-1.11M | $-269.00K | $6.52M | $6.16M | $5.61M | $-2.70M | $7.11M | $4.23M | $5.91M | $-2.56M | $5.91M | $3.50M | $4.50M | $-2.14M | $4.98M | $5.80M |
| Other Current Assets | $1.07M | $1.96M | $805.00K | $792.00K | $5.77M | $7.39M | $765.00K | $555.00K | $805.00K | $9.58M | $522.00K | $516.00K | $387.00K | $7.56M | $1.16M | $997.00K | $966.00K | $8.66M | $247.00K | $329.00K |
| Total Current Assets | $91.84M | $100.26M | $109.17M | $128.84M | $72.33M | $99.67M | $126.23M | $142.08M | $170.92M | $199.15M | $211.66M | $233.52M | $242.06M | $267.24M | $228.99M | $251.02M | $265.35M | $195.70M | $213.71M | $98.19M |
| Property Plant Equipment Net | $110.00K | $432.00K | $912.00K | $4.55M | $5.43M | $3.95M | $3.22M | $3.62M | $3.87M | $4.13M | $4.22M | $3.99M | $2.93M | $3.06M | $3.31M | $3.58M | $3.41M | $3.70M | $2.67M | $2.74M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $400.00K | $400.00K | $400.00K | $400.00K | $283.00K | $- | $- | $492.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $- | $40.00K | $40.00K | $4.96M | $323.00K | $41.00K | $53.00K | $555.00K | $566.00K | $576.00K | $586.00K | $918.00K | $928.00K | $957.00K | $968.00K | $974.00K | $1.12M | $825.00K | $1.06M |
| Total Non-Current Assets | $510.00K | $832.00K | $1.35M | $4.99M | $10.68M | $4.27M | $3.26M | $4.16M | $4.42M | $4.69M | $4.79M | $4.58M | $3.85M | $3.99M | $4.27M | $4.55M | $4.38M | $4.81M | $3.50M | $3.80M |
| Other Assets | $- | $-0 | $- | $- | $0 | $- | $-0 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $92.35M | $101.09M | $110.52M | $133.84M | $83.00M | $103.95M | $129.50M | $146.24M | $175.34M | $203.84M | $216.45M | $238.09M | $245.91M | $271.23M | $233.25M | $255.57M | $269.73M | $200.51M | $217.21M | $101.99M |
| Account Payables | $243.00K | $27.00K | $910.00K | $1.07M | $591.00K | $384.00K | $1.81M | $28.00K | $4.04M | $3.49M | $2.97M | $2.03M | $2.70M | $2.68M | $2.31M | $2.62M | $2.13M | $3.95M | $1.41M | $2.57M |
| Short Term Debt | $224.00K | $878.00K | $1.65M | $2.25M | $2.63M | $999.00K | $- | $-183.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $5.00M | $8.34M | $- | $- | $- | $183.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $3.04M | $5.45M | $1.00K | $4.00K | $11.08M | $11.73M | $14.38M | $12.76M | $13.09M | $15.90M | $19.83M | $14.92M | $10.07M | $13.93M | $22.74M | $12.79M | $10.64M | $10.07M | $8.50M | $6.19M |
| Total Current Liabilities | $3.51M | $6.35M | $7.56M | $11.66M | $11.67M | $12.12M | $16.19M | $12.79M | $17.13M | $19.39M | $22.79M | $16.95M | $12.77M | $16.61M | $25.05M | $15.41M | $12.77M | $14.02M | $9.91M | $8.77M |
| Long Term Debt | $- | $- | $105.00K | $134.00K | $18.34M | $16.46M | $15.21M | $15.10M | $15.02M | $14.95M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $-2.63M | $-999.00K | $10.00K | $12.00K | $30.00K | $30.00K | $90.00K | $150.00K | $214.00K | $276.00K | $331.00K | $370.00K | $430.00K | $484.00K | $535.00K | $590.00K |
| Total Non-Current Liabilities | $- | $- | $105.00K | $134.00K | $18.34M | $16.46M | $15.21M | $15.12M | $15.05M | $14.97M | $90.00K | $150.00K | $214.00K | $276.00K | $331.00K | $370.00K | $430.00K | $484.00K | $535.00K | $590.00K |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $3.51M | $6.35M | $7.66M | $11.80M | $30.01M | $28.58M | $31.41M | $27.90M | $32.18M | $34.36M | $22.88M | $17.10M | $12.98M | $16.89M | $25.38M | $15.78M | $13.20M | $14.50M | $10.45M | $9.36M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $3.00K | $3.00K | $2.00K |
| Retained Earnings | $-484.08M | $-477.27M | $-468.49M | $-446.91M | $-514.39M | $-489.43M | $-464.40M | $-441.43M | $-413.38M | $-383.54M | $-355.31M | $-322.70M | $-291.31M | $-264.42M | $-236.28M | $-199.50M | $-170.68M | $-144.70M | $-122.04M | $-104.90M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $-0 | $- | $- | $- | $- | $-0 | $- | $- | $- | $-3.01M | $-2.71M | $- | $-2.13M | $-1.82M | $-1.52M | $-1.23M | $-989.00K | $-774.00K |
| Other Total Stockholders Equity | $572.92M | $572.01M | $571.34M | $568.95M | $567.38M | $564.80M | $562.48M | $559.77M | $556.53M | $553.01M | $548.88M | $546.70M | $526.95M | $518.76M | $446.29M | $441.11M | $428.71M | $331.95M | $329.79M | $198.30M |
| Total Stockholders Equity | $88.84M | $94.74M | $102.86M | $122.04M | $53.00M | $75.37M | $98.09M | $118.34M | $143.16M | $169.48M | $193.57M | $220.99M | $232.93M | $254.34M | $207.87M | $239.79M | $256.52M | $186.01M | $206.76M | $92.63M |
| Total Equity | $88.84M | $94.74M | $102.86M | $122.04M | $53.00M | $75.37M | $98.09M | $118.34M | $143.16M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Stockholders Equity | $92.35M | $101.09M | $110.52M | $133.84M | $83.00M | $103.95M | $129.50M | $146.24M | $175.34M | $203.84M | $216.45M | $238.09M | $245.91M | $271.23M | $233.25M | $255.57M | $269.73M | $200.51M | $217.21M | $101.99M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $92.35M | $101.09M | $110.52M | $133.84M | $83.00M | $103.95M | $129.50M | $146.24M | $175.34M | $203.84M | $216.45M | $238.09M | $245.91M | $271.23M | $233.25M | $255.57M | $269.73M | $200.51M | $217.21M | $101.99M |
| Total Investments | $400.00K | $400.00K | $400.00K | $400.00K | $283.00K | $- | $- | $492.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $224.00K | $878.00K | $1.75M | $2.38M | $18.34M | $17.46M | $15.21M | $15.10M | $15.02M | $14.95M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Debt | $-90.54M | $-97.42M | $-104.09M | $-122.31M | $-53.99M | $-75.10M | $-100.76M | $-117.31M | $-146.64M | $-174.62M | $-201.37M | $-226.44M | $-233.03M | $-259.68M | $-219.55M | $-244.38M | $-257.69M | $-187.04M | $-206.36M | $-90.35M |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $12.16M | $-105.89M | $-119.13M | $-119.71M | $-72.97M |
| Depreciation and Amortization | $617.00K | $1.44M | $1.40M | $1.21M | $850.00K |
| Deferred Income Tax | $377.00K | $- | $- | $- | $- |
| Stock Based Compensation | $6.89M | $11.52M | $18.58M | $15.63M | $6.80M |
| Change in Working Capital | $-4.29M | $-7.40M | $1.30M | $4.24M | $-2.18M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $-357.00K | $-3.10M | $804.00K | $-881.00K | $1.03M |
| Other Working Capital | $-3.93M | $-4.30M | $493.00K | $5.12M | $-3.21M |
| Other Non Cash Items | $-78.94M | $3.12M | $-174.00K | $-163.00K | $-172.00K |
| Net Cash Provided by Operating Activities | $-63.19M | $-97.21M | $-98.03M | $-98.80M | $-67.67M |
| Investments in Property Plant and Equipment | $-8.00K | $-267.00K | $-2.46M | $-1.18M | $-1.58M |
| Acquisitions Net | $1.35M | $- | $- | $- | $- |
| Purchases of Investments | $-85.08M | $- | $- | $- | $- |
| Sales Maturities of Investments | $83.74M | $- | $- | $- | $- |
| Other Investing Activities | $85.08M | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $85.08M | $-267.00K | $-2.46M | $-1.18M | $-1.58M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $321.00K | $262.00K | $15.47M | $172.18M | $129.47M |
| Common Stock Repurchased | $86.00K | $- | $-205.00K | $166.00K | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-16.03M | $262.00K | $30.37M | $172.62M | $129.99M |
| Net Cash Used Provided by Financing Activities | $-16.03M | $262.00K | $30.37M | $172.62M | $129.99M |
| Effect of Forex Changes on Cash | $-400.00K | $- | $- | $- | $- |
| Net Change in Cash | $5.46M | $-97.21M | $-70.11M | $72.64M | $60.74M |
| Cash at End of Period | $98.30M | $92.85M | $190.06M | $260.17M | $187.53M |
| Cash at Beginning of Period | $92.85M | $190.06M | $260.17M | $187.53M | $126.79M |
| Operating Cash Flow | $-63.19M | $-97.21M | $-98.03M | $-98.80M | $-67.67M |
| Capital Expenditure | $-8.00K | $-267.00K | $-2.46M | $-1.18M | $-1.58M |
| Free Cash Flow | $-63.20M | $-97.47M | $-100.49M | $-99.98M | $-69.25M |
Cash Flow Charts
| Breakdown | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-6.81M | $-8.79M | $-21.58M | $67.48M | $-24.96M | $-25.03M | $-22.97M | $-28.05M | $-29.83M | $-28.23M | $-32.61M | $-31.39M | $-26.90M | $-28.13M | $-36.78M | $-28.83M | $-25.97M | $-22.66M | $-17.14M | $-16.05M |
| Depreciation and Amortization | $- | $- | $- | $289.00K | $328.00K | $335.00K | $352.00K | $354.00K | $399.00K | $436.00K | $374.00K | $298.00K | $291.00K | $309.00K | $314.00K | $301.00K | $283.00K | $245.00K | $215.00K | $200.00K |
| Deferred Income Tax | $- | $83.74M | $- | $-83.74M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $878.00K | $607.00K | $2.22M | $1.53M | $2.53M | $2.25M | $2.66M | $3.23M | $3.38M | $4.08M | $5.17M | $4.69M | $4.63M | $4.10M | $4.80M | $3.90M | $2.82M | $1.89M | $1.80M | $1.66M |
| Change in Working Capital | $-1.96M | $-508.00K | $-3.12M | $-1.80M | $1.14M | $-4.26M | $3.53M | $-4.67M | $-1.99M | $-2.18M | $2.30M | $6.49M | $-5.31M | $-6.76M | $6.84M | $3.67M | $487.00K | $2.00M | $1.79M | $-3.73M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $216.00K | $-883.00K | $-161.00K | $480.00K | $207.00K | $-1.43M | $1.79M | $-4.01M | $551.00K | $520.00K | $937.00K | $-627.00K | $-26.00K | $382.00K | $-333.00K | $513.00K | $-1.44M | $2.15M | $-1.15M | $-645.00K |
| Other Working Capital | $-2.18M | $375.00K | $-2.96M | $-2.28M | $936.00K | $-2.83M | $1.74M | $-665.00K | $-2.54M | $-2.70M | $1.36M | $7.11M | $-5.29M | $-7.14M | $7.17M | $3.15M | $1.93M | $-157.00K | $2.95M | $-3.09M |
| Other Non Cash Items | $984.00K | $655.00K | $2.26M | $1.58M | $672.00K | $3.03M | $17.00K | $35.00K | $36.00K | $-15.00K | $-53.00K | $-54.00K | $-52.00K | $-12.00K | $-43.00K | $-55.00K | $-53.00K | $-49.00K | $-42.00K | $-41.00K |
| Net Cash Provided by Operating Activities | $-7.57M | $-8.03M | $-20.22M | $-14.65M | $-20.28M | $-23.67M | $-16.41M | $-29.11M | $-28.01M | $-25.90M | $-24.82M | $-19.96M | $-27.34M | $-30.49M | $-24.86M | $-21.02M | $-22.43M | $-18.58M | $-13.38M | $-17.96M |
| Investments in Property Plant and Equipment | $- | $- | $- | $- | $-8.00K | $-149.00K | $-86.00K | $-149.00K | $-32.00K | $-850.00K | $-267.00K | $-1.23M | $-115.00K | $-81.00K | $-31.00K | $-488.00K | $-577.00K | $-766.00K | $-78.00K | $-401.00K |
| Acquisitions Net | $- | $150.00K | $1.20M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $-83.74M | $- | $83.74M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $150 | $1.20K | $83.74K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $- | $150.00K | $1.20M | $83.74M | $-8.00K | $-149.00K | $-86.00K | $-149.00K | $-32.00K | $-850.00K | $-267.00K | $-1.23M | $-115.00K | $-81.00K | $-31.00K | $-488.00K | $-577.00K | $-766.00K | $-78.00K | $-401.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $30.00K | $59.00K | $178.00K | $29.00K | $55.00K | $59.00K | $60.00K | $1.00K | $142.00K | $48.00K | $22.00K | $14.55M | $850.00K | $70.42M | $93.63M | $8.13M | $93.63M | $-129.44M | $129.47M | $- |
| Common Stock Repurchased | $- | $13.00K | $73.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $166.00K | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $30.00K | $59.00K | $178.00K | $-16.32M | $55.00K | $59.00K | $60.00K | $1.00K | $142.00K | $14.95M | $22.00K | $14.61M | $799.00K | $70.70M | $60.00K | $8.19M | $93.66M | $30.00K | $129.47M | $238.00K |
| Net Cash Used Provided by Financing Activities | $30.00K | $59.00K | $178.00K | $-16.32M | $55.00K | $59.00K | $60.00K | $1.00K | $142.00K | $14.95M | $22.00K | $14.61M | $799.00K | $70.70M | $60.00K | $8.19M | $93.66M | $30.00K | $129.47M | $238.00K |
| Effect of Forex Changes on Cash | $- | $438.00K | $-438.00K | $- | $- | $149.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-7.54M | $-7.82M | $-18.85M | $52.76M | $-20.24M | $-23.61M | $-16.44M | $-29.25M | $-27.90M | $-11.80M | $-25.07M | $-6.59M | $-26.66M | $40.14M | $-24.83M | $-13.31M | $70.65M | $-19.32M | $116.01M | $-18.13M |
| Cash at End of Period | $90.76M | $98.30M | $106.53M | $125.37M | $72.61M | $92.85M | $116.46M | $132.90M | $162.16M | $190.06M | $201.86M | $226.93M | $233.52M | $260.17M | $220.04M | $244.87M | $258.19M | $187.53M | $206.85M | $90.84M |
| Cash at Beginning of Period | $98.30M | $106.12M | $125.37M | $72.61M | $92.85M | $116.46M | $132.90M | $162.16M | $190.06M | $201.86M | $226.93M | $233.52M | $260.17M | $220.04M | $244.87M | $258.19M | $187.53M | $206.85M | $90.84M | $108.97M |
| Operating Cash Flow | $-7.57M | $-8.03M | $-20.22M | $-14.65M | $-20.28M | $-23.67M | $-16.41M | $-29.11M | $-28.01M | $-25.90M | $-24.82M | $-19.96M | $-27.34M | $-30.49M | $-24.86M | $-21.02M | $-22.43M | $-18.58M | $-13.38M | $-17.96M |
| Capital Expenditure | $- | $- | $- | $- | $-8.00K | $-149.00K | $-86.00K | $-149.00K | $-32.00K | $-850.00K | $-267.00K | $-1.23M | $-115.00K | $-81.00K | $-31.00K | $-488.00K | $-577.00K | $-766.00K | $-78.00K | $-401.00K |
| Free Cash Flow | $-7.57M | $-8.03M | $-20.22M | $-14.65M | $-20.29M | $-23.82M | $-16.50M | $-29.25M | $-28.05M | $-26.75M | $-25.09M | $-21.19M | $-27.45M | $-30.57M | $-24.89M | $-21.51M | $-23.01M | $-19.35M | $-13.46M | $-18.37M |
AVROBIO Dividends
Explore AVROBIO's dividend history, including dividend yield, payout ratio, and historical payments.
AVROBIO News
Read the latest news about AVROBIO, including recent articles, headlines, and updates.
Tectonic Therapeutic Appoints Daniel Lochner as Chief Financial Officer
WATERTOWN, Mass.--(BUSINESS WIRE)--Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic. “Dan is an experienced public-company CFO who will add significant financial expertise to our team,” said Alise Reicin, MD, President and Chief Executive Officer of Tectonic. “With his extensive background in the healt.
AVROBIO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVRO
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AVROBIO, Inc. (NasdaqGS: AVRO) and Tectonic Therapeutic, Inc. pursuant to which pre-merger AVROBIO shareholders are expected to own approximately 22.3% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Co.
AVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVRO
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AVROBIO, Inc. (NasdaqGS: AVRO) and Tectonic Therapeutic, Inc. pursuant to which pre-merger AVROBIO shareholders are expected to own approximately 22.3% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Co.
Shareholder Alert: Ademi LLP investigates whether AVROBIO, Inc. has obtained a Fair Price in its transaction with Tectonic
MILWAUKEE , Jan. 31, 2024 /PRNewswire/ -- Ademi LLP is investigating AVROBIO, Inc. (Nasdaq: AVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Tectonic. Click here to learn how to join the https://www.ademilaw.com/case/avrobio-inc or call Guri Ademi toll-free at 866-264-3995.
AVRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of AVROBIO, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of AVROBIO, Inc. (NASDAQ: AVRO) and Tectonic Therapeutic, Inc. is fair to AVROBIO shareholders. Upon completion of the proposed transaction, pre-merger AVROBIO shareholders are expected to own approximately 22.3% of the combined company. Halper Sadeh encourages AVROBIO shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper.
AVROBIO and Tectonic Therapeutic Announce Merger
CAMBRIDGE, Mass. & WATERTOWN, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO) and Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction (the “Merger”). Under the terms of the agreement, AVR.
Avrobio: Net-Net Biotech Pursuing Strategic Alternatives
After monetizing one of its pipeline candidates, Avrobio has cash well in excess of its market cap. The company announced its search for strategic alternatives recently. The process could close its valuation gap soon. There is potential for significantly more value if Avrobio can also monetize its remaining candidates.
AVROBIO to Explore Strategic Alternatives
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. AVROBIO has made the determination to halt further development of its programs and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. As part o.
How to Handle Penny Stocks Volatility in 2023
Penny stocks continue to offer incredible opportunities for investors in 2023. As high-growth, micro-cap equities, they have the potential to outperform traditional stocks, particularly given their inherent affordability, which allows for a broader, more diversified portfolio.
Why Is AVROBIO (AVRO) Stock Up 83% Today?
AVROBIO (NASDAQ: AVRO ) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NYSE: NVS ). This deal has Novartis agreeing to pay $87.5 million in cash to AVROBIO for an investigational hematopoietic stem cell ( HSC ) gene therapy program.
AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study
AVROBIO Inc (NASDAQ: AVRO) reported new interim data from the Phase 1/2 gene therapy trial of AVR-RD-04 for cystinosis. Cystinosis is a condition characterized by the accumulation of the amino acid cystine (a building block of proteins) within cells.
After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data
Avrobio Inc's AVRO gene therapy for a rare lysosomal storage disorder showed potential durability in the first three patients more than one year after infusion. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 19.7% in 4 Weeks
The heavy selling pressure might have exhausted for AVROBIO, Inc. (AVRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
AVROBIO to Present at Cowen's 2nd Annual Genetic Medicines Summit
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced Azadeh Golipour, Ph.D., chief technology officer at AVROBIO, will present virtually at Cowen's 2nd Annual Genetic Medicines Summit at 2:00 p.m. ET on Thursday, Feb. 3, 2022. About AVROBIO Our vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease throu
AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that updated clinical data from its ongoing, collaborator-sponsoredi Phase 1/2 clinical trial in cystinosis will be presented on Feb. 9, 2022, at the 18th Annual WORLDSymposium™ in San Diego, Calif. Additionally, preclinical data from its Pompe disease and Hunter syndrome programs, as well as data on its
Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 44.1% in 4 Weeks
AVROBIO, Inc. (AVRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
AVROBIO down 30% as it reprioritizes pipeline programs
AVROBIO Inc (NASDAQ: AVRO) dropped by 30% after announcing it was changing its portfolio priorities to concentrate on other clinical-stage pipeline programs. The company plans to deprioritize the Fabry program because of several reasons, including new clinical findings from the most recent patients given the Phase II FAB-GT drug candidate.
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 83,750 shares of the company's common stock to four new employees as inducement awards under the company's 2019 Inducement Plan. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4). The st
AVROBIO to Participate at Four Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in four upcoming virtual investor conferences. Citi's 16th Annual BioPharma Virtual Conference Date: Wednesday, Sept. 8 - Friday, Sept. 10, 2021 1x1 meetings only 2021 Wells Fargo Virtual Healthcare Conference Presentation date: Thurs
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for AVRO.